Atherosclerosis vaccine - AVANT Immunotherapeutics
Alternative Names: CETi-1; CETP vaccine - AVANT; Cholesteryl ester transfer protein vaccine - AVANTLatest Information Update: 18 Jun 2007
At a glance
- Originator AVANT Immunotherapeutics
- Class Antihyperlipidaemics; Vaccines
- Mechanism of Action Cholesterol ester transfer protein inhibitors; Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Atherosclerosis; Low HDL cholesterol
Most Recent Events
- 03 May 2007 AVANT is seeking partnerships for its cardiovascular programmes (http://www.avantimmune.com)
- 03 May 2007 Discontinued - Phase-II for Atherosclerosis in USA (Injection)
- 03 May 2007 Discontinued - Phase-II for Low HDL cholesterol in USA (Injection)